Plain-English translation of NCT06010329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called sutetinib maleate to see if it can effectively treat advanced or spreading lung cancer in patients whose cancer has uncommon changes in a gene called EGFR. The medication works by blocking proteins that help cancer cells grow. Researchers want to learn whether this treatment works well and is safe for people with this specific type of lung cancer.
Most lung cancer treatments target common EGFR mutations, but some patients have uncommon mutations that don't respond as well to standard therapies. This trial exists to find a better treatment option for people with these less common genetic changes.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth in capsule form, following a 28-day treatment cycle as directed by the study doctors, with or without food. The trial is open-label, meaning you and your doctors will know you're receiving this new treatment. You would need to visit the clinic for regular check-ups, blood tests, and imaging scans to monitor how the medication is working and check for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States